TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING

This publication has 10 references indexed in Scilit:

• Serum testosterone—A significant determinant of metastatic relapse for irradiated localized prostate cancer
  Urology, 1997
• A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate Cancer
  Journal of Urology, 1996
• Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
  Urology, 1995
• Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group
  Urology, 1995
• Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy
  International Journal of Radiation Oncology*Biology*Physics, 1994
• The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer
  Urology, 1994
• Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
  The Prostate, 1992
• Endocrine Therapy for Prostate Cancer
  Endocrinology and Metabolism Clinics of North America, 1991
• CIRCANNUAL CYCLE IN PLASMA TESTOSTERONE LEVELS IN MAN.
  Journal of Clinical Endocrinology & Metabolism, 1976